These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 28398333)

  • 41. Pharmacokinetics of serelaxin in patients with hepatic impairment: a single-dose, open-label, parallel group study.
    Kobalava Z; Villevalde S; Kotovskaya Y; Hinrichsen H; Petersen-Sylla M; Zaehringer A; Pang Y; Rajman I; Canadi J; Dahlke M; Lloyd P; Halabi A
    Br J Clin Pharmacol; 2015 Jun; 79(6):937-45. PubMed ID: 25511105
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serelaxin: insights into its haemodynamic, biochemical, and clinical effects in acute heart failure.
    Hernandez AV
    Eur Heart J; 2014 Feb; 35(7):410-2. PubMed ID: 24277752
    [No Abstract]   [Full Text] [Related]  

  • 43. Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial.
    Dschietzig T; Teichman S; Unemori E; Wood S; Boehmer J; Richter C; Baumann G; Stangl K
    J Card Fail; 2009 Apr; 15(3):182-90. PubMed ID: 19327619
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Renal hemodynamic effects of serelaxin in patients with chronic heart failure: a randomized, placebo-controlled study.
    Voors AA; Dahlke M; Meyer S; Stepinska J; Gottlieb SS; Jones A; Zhang Y; Laurent D; Slart RH; Navis GJ
    Circ Heart Fail; 2014 Nov; 7(6):994-1002. PubMed ID: 25286914
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Vasoactive and inotropic drugs in acute heart failure].
    Ruiz-Laiglesia FJ; Camafort-Babkowski M
    Med Clin (Barc); 2014 Mar; 142 Suppl 1():49-54. PubMed ID: 24930084
    [TBL] [Abstract][Full Text] [Related]  

  • 46. One step forward for serelaxin as a promising therapy in cardiac fibrosis.
    Fernández-Alfonso MS; Ruilope LM
    Hypertension; 2014 Aug; 64(2):229-30. PubMed ID: 24866133
    [No Abstract]   [Full Text] [Related]  

  • 47. Serelaxin is a more efficacious antifibrotic than enalapril in an experimental model of heart disease.
    Samuel CS; Bodaragama H; Chew JY; Widdop RE; Royce SG; Hewitson TD
    Hypertension; 2014 Aug; 64(2):315-22. PubMed ID: 24866131
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A randomized, double-blind, placebo-controlled trial of the safety of vaginal recombinant human relaxin for cervical ripening.
    Bell RJ; Permezel M; MacLennan A; Hughes C; Healy D; Brennecke S
    Obstet Gynecol; 1993 Sep; 82(3):328-33. PubMed ID: 8355929
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluating the Efficacy, Safety, and Tolerability of Serelaxin When Added to Standard Therapy in Asian Patients With Acute Heart Failure: Design and Rationale of RELAX-AHF-ASIA Trial.
    Sato N; Lam CS; Teerlink JR; Greenberg BH; Tsutsui H; Oh BH; Zhang J; Lefkowitz M; Hua TA; Holbro T; Marshood M; Wang XL; Ge J
    J Card Fail; 2017 Jan; 23(1):63-71. PubMed ID: 27825893
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Relaxin family peptide receptors--from orphans to therapeutic targets.
    van der Westhuizen ET; Halls ML; Samuel CS; Bathgate RA; Unemori EN; Sutton SW; Summers RJ
    Drug Discov Today; 2008 Aug; 13(15-16):640-51. PubMed ID: 18675759
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Relaxin: a new approach for the treatment of acute congestive heart failure.
    Grossman J; Frishman WH
    Cardiol Rev; 2010; 18(6):305-12. PubMed ID: 20926940
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Editor's Choice-Recent therapeutic trials on fluid removal and vasodilation in acute heart failure.
    Ennezat PV; Stewart M; Samson R; Bouabdallaoui N; Maréchaux S; Banfi C; Bouvaist H; Le Jemtel TH
    Eur Heart J Acute Cardiovasc Care; 2016 Feb; 5(1):86-95. PubMed ID: 25414321
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Acute cardiac insufficiency. Do we finally have an opportunity to improve the prognosis?].
    Formiga F; Manzano Espinoza L
    Med Clin (Barc); 2014 Mar; 142 Suppl 1():1-2. PubMed ID: 24930075
    [No Abstract]   [Full Text] [Related]  

  • 54. Relaxin-2 may offer therapeutic advantages in end-stage heart failure.
    Zhao Z; Liu T; Li G
    Int J Cardiol; 2012 Jun; 157(3):432-3. PubMed ID: 22541981
    [No Abstract]   [Full Text] [Related]  

  • 55. The other serelaxin in acute heart failure study: lessons from a pragmatic clinical trial.
    Kalogeropoulos AP; Butler J
    Eur J Heart Fail; 2019 Mar; 21(3):334-336. PubMed ID: 30688399
    [No Abstract]   [Full Text] [Related]  

  • 56. The role of intravenous vasodilators in acute heart failure management.
    Piper S; McDonagh T
    Eur J Heart Fail; 2014 Aug; 16(8):827-34. PubMed ID: 25100108
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Day vs night: Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX-AHF trial.
    Pang PS; Teerlink JR; Boer-Martins L; Gimpelewicz C; Davison BA; Wang Y; Voors AA; Severin T; Ponikowski P; Hua TA; Greenberg BH; Filippatos G; Felker GM; Cotter G; Metra M
    Am Heart J; 2017 May; 187():62-69. PubMed ID: 28454809
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeting arterial remodeling: a key tile in the mosaic of the therapeutic effects of relaxin in cardiovascular disease.
    Bani D
    Hypertension; 2010 May; 55(5):1095-6. PubMed ID: 20351339
    [No Abstract]   [Full Text] [Related]  

  • 59. The positive inotropic effect of relaxin-2 in human atrial myocardium is preserved in end-stage heart failure: role of G(i)-phosphoinositide-3 kinase signaling.
    Dschietzig T; Alexiou K; Kinkel HT; Baumann G; Matschke K; Stangl K
    J Card Fail; 2011 Feb; 17(2):158-66. PubMed ID: 21300306
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The year in cardiology: heart failure 2014.
    Voors AA; Ruschitzka F
    Eur Heart J; 2015 Feb; 36(7):421-4. PubMed ID: 25575601
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.